Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72,075 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy.
Lee H, Ferguson AL, Quek C, Vergara IA, Pires daSilva I, Allen R, Gide TN, Conway JW, Koufariotis LT, Hayward NK, Waddell N, Carlino MS, Menzies AM, Saw RPM, Shklovskaya E, Rizos H, Lo S, Scolyer RA, Long GV, Palendira U, Wilmott JS. Lee H, et al. Clin Cancer Res. 2023 Jul 5;29(13):2513-2524. doi: 10.1158/1078-0432.CCR-22-2657. Clin Cancer Res. 2023. PMID: 36790412
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.
Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, Lim SY, Nur Gide T, Shang P, Attrill GH, Madore J, Edwards J, Carlino MS, Guminski A, Saw RPM, Thompson JF, Ferguson PM, Palendira U, Menzies AM, Long GV, Scolyer RA, Wilmott JS. Lee H, et al. Oncoimmunology. 2018 Oct 31;8(2):e1537581. doi: 10.1080/2162402X.2018.1537581. eCollection 2019. Oncoimmunology. 2018. PMID: 30713793 Free PMC article.
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Wilmott JS, et al. Among authors: lee h. Clin Cancer Res. 2023 Feb 1;29(3):521-531. doi: 10.1158/1078-0432.CCR-22-2581. Clin Cancer Res. 2023. PMID: 36477181 Free PMC article. Clinical Trial.
Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas.
Edwards J, Ferguson PM, Lo SN, Pires da Silva I, Colebatch AJ, Lee H, Saw RPM, Thompson JF, Menzies AM, Long GV, Newell F, Pearson JV, Waddell N, Hayward NK, Johansson PA, Mann GJ, Scolyer RA, Palendira U, Wilmott JS. Edwards J, et al. Among authors: lee h. Cancer Immunol Res. 2020 Nov;8(11):1346-1353. doi: 10.1158/2326-6066.CIR-19-0835. Epub 2020 Sep 11. Cancer Immunol Res. 2020. PMID: 32917657
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM. Long GV, et al. Among authors: lee h, lee jh. Lancet Oncol. 2019 Jul;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6. Epub 2019 Jun 3. Lancet Oncol. 2019. PMID: 31171444 Clinical Trial.
72,075 results
You have reached the last available page of results. Please see the User Guide for more information.